DRUG TREATMENT SAVING HORSE'S LIVES
Private Placement Offering Event Set for June 27th at Lone
DENVER, Colorado -- June 13, 2014 - Willowcroft
Pharm, Inc., developer of the successful laminitis drug treatment, Laminil,
announced today that it is offering up to 60,000,000 shares of preferred stock at a
price of $0.08333 per share. Willowcroft Pharm intends to use the net proceeds
for securing FDA approval and commercialization of Laminil. The closing date of
the offering is expected to be August 1st. The offering event is
scheduled for Friday, June 27th at 8:30 PM.
The company noted that the injectable drug is being
successfully tested around the world at major veterinary clinics. In over one
year of Laminil use, one clinic stated, "We have not had to euthanize
a single laminitis horse since using Laminil."
Please visit Laminil.us to
learn more about this opportunity to invest at the ground floor and be a part
of the solution to a centuries old fatal disease.
First Post the day of the event is set for 6:35 PM.
Laminil is an injectable drug developed to halt
the inflammatory response and laminitis cascade of acute laminitis and active
chronic laminitis. Laminitis is a crippling and often fatal disease, characterized
by inflammation of the tissues that connect the hoof wall to the coffin bone in
a horse's foot. Laminil is an investigational drug going through the FDA
approval process. Laminil has shown promise with all types of laminitis, such
as insulin resistance, equine metabolic syndrome, grain overload, grass
founder, trauma and single limb laminitis.
About Willowcroft Pharm, Inc.:
Willowcroft Pharm, Inc., is a privately held
pharmaceutical company engaged in saving horses and other animals, from the
debilitating, painful and life-threatening disease laminitis. For more information
about Willowcroft Pharm, Inc., and the Laminil development program, please
shares offered in the private placement have not been registered under the
Securities Act of 1933, as amended, or state securities laws, and may not be
offered or sold in the United States without being registered with the Securities
and Exchange Commission (SEC) or through an applicable exemption from SEC
registration requirements. The shares of
preferred stock are offered only to accredited investors.
: This press release contains forward-looking statements that
involve significant risks and uncertainties. Any statement describing the
Company's expectations or beliefs is a forward-looking statement, as defined in
the Private Securities Litigation Reform Act of 1995, and should be considered
an at-risk statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of developing and
commercializing drugs, including the likelihood and potential benefit to the
Company's stockholders of the Company entering into a strategic transaction,
the adequacy of the Company's capital to support the Company's operations, the
potential of the Company's Laminil market authorization. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect, would cause
its results to differ materially from those expressed or implied by such
forward-looking statements. Forward-looking statements contained in this
announcement are made as of this date, and the Company undertakes no obligation
to publicly update any forward-looking statement, whether as a result of new
information, future events or otherwise.